Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia.

W G Wierda1, T J Kipps

  • 1Department of Medicine, University of California, San Diego, La Jolla 92093-0663, USA.

Current Opinion in Hematology
|July 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies.

Journal of hematology & oncology·2026
Same author

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.

Blood·2020
Same author

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.

Leukemia·2017
Same author

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Leukemia·2017
Same author

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.

Leukemia·2017
Same author

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.

Leukemia·2017
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Recent advances in understanding B cell chronic lymphocytic leukemia (CLL) biology and treatment have identified key genetic factors and molecular subgroups. Research offers insights into drug resistance and immune deficiency, guiding new therapeutic strategies.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Significant progress has been made in understanding the biology and treatment of B cell chronic lymphocytic leukemia (CLL).
  • Recent studies have identified cytogenetic and molecular lesions implicated in leukemogenesis and disease progression.
  • Molecular analyses of immunoglobulin genes suggest distinct CLL subgroups with potentially different clinical behaviors.

Purpose of the Study:

  • To review recent advancements in the understanding of CLL biology and treatment.
  • To highlight key findings in genetic lesions, molecular subgroups, drug resistance, and immune dysfunction in CLL.
  • To discuss prognostic factors and emerging therapies for CLL patients.

Main Methods:

  • Review of recent cytogenetic and molecular studies.

Related Experiment Videos

  • Analysis of immunoglobulin gene mutations.
  • Biochemical and immunological investigations of CLL cells.
  • Evaluation of clinical studies on prognostic factors and novel therapies.

    • Main Results:

    • Identification of specific cytogenetic and molecular lesions contributing to CLL development and progression.
    • Delineation of CLL subgroups based on immunoglobulin gene analysis, correlating with clinical behavior.
    • Insights into the biochemical mechanisms of drug resistance in CLL cells.
    • Understanding of how CLL cells contribute to immune deficiency in patients.
    • Identification of prognostic factors and promising new therapies including stem cell transplantation, monoclonal antibodies, and gene therapy.

    Conclusions:

    • Recent research has significantly advanced the understanding of CLL biology, pathogenesis, and treatment.
    • Molecular and immunological insights are crucial for stratifying patients and developing targeted therapies.
    • Emerging therapeutic strategies offer new hope for improving outcomes in CLL.